To further study the crosstalk mechanistically between USP1 and those newly established genetic subtypes that carry a poor outcome, we collected the additional 59 cases of relapsed/refractory (newly diagnosed) DLBCL patient samples containing MCD (including MYD88L265P and CD79B mutations), N1 (including NOTCH1 mutations) subtypes and analyzed the expression of USP1 by using immunohistochemistry analysis. The gene discussed is NOTCH1; the disease is diffuse large B-cell lymphoma.